TREATMENT OF ULCER BY USING SIDDHA HERBAL FORMULATION OF AMALAKATHI KIRUTHAM

CLINICAL TRIAL OF SIDDHA HERBAL FORMULATION AMALAKATHI KIRUTHAM IN THE TREATMENT OF ERIGUNMAM ACID PEPTIC DISEASE - CLINICAL TRIAL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/08/035861

Enrollment

Registered

2021-08-24

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K00-K95- Diseases of the digestive system

Interventions

Intervention1: Amalakathi kirutham: Amalakathi kirutham in the treatment of Erigunmam 4ml twice a day 48 days Control Intervention1: nil AMALAKATHI KIRUTHAM: AMALAKATHI KIRUTHAM IN THE TREAMENT OF

Eligibility

Inclusion criteria

Inclusion criteria: Patient with the symptoms of erigunmam such as burning or gnawing sensation in stomach, headache, burping, increased salivation, colic pain, diarrhoea, sweating, giddiness

Exclusion criteria

Exclusion criteria: pregnancy & Lactation, gastric carcinoma, pancreatitis, liver disorders, worm infestations,abdominal curvature of spine curvature

Design outcomes

Primary

Measure	Time frame
Primary outcome is mainly assessed by comparing the reduction of clinical symptoms before and after treatment by using GSRS scaleTimepoint: 1 YEAR	—

Secondary

Measure	Time frame
SECONDARY OUTCOME IS ASSESSED BY THE DISEASE RELATED TO AGE,SEX, DIETARY HABITS, SOCIO ECONOMIC STATUS, FAMILY HISTORY ETC, SECONDARY IS MAINLY ASSESSED BY COMPARING THE CLINICAL SYMPTOMS BEFORE AND AFTER TREATMENT BY USING ENDOSCOPYTimepoint: FOURTY NINTH DAY	—

Countries

India

Contacts

Public ContactDR V ABINAYA ARULMALAR

NATIONAL INSTITUTE OF SIDDHA

dr.h.nalinisofia@gmail.com8939899363

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026